A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer

  • Haydon, Andrew (Primary Chief Investigator (PCI))
  • Brooks, Christine (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date26/10/22 → 25/10/24

Keywords

  • Clinical Trials
  • Metastatic cancer
  • AU-007

Clinical Trial Phase

  • Phase I
  • Phase II